2 Clarke Drive
Suite 100
Cranbury, NJ 08512
© 2024 MJH Life Sciences™ and OncLive - Clinical Oncology News, Cancer Expert Insights. All rights reserved.
Jean-Yves Blay, MD, PhD, professor of medicine at the Université Claude Bernard, Lyon, France, and the scientific director of the Canceropole Lyon Rhône Alpes, discusses the treatment landscape of sarcoma.
Jean-Yves Blay, MD, PhD, professor of medicine at the Université Claude Bernard, Lyon, France, and the scientific director of the Canceropole Lyon Rhône Alpes, discusses the treatment landscape of sarcoma.
From a clinical research standpoint, it is very difficult to develop trials for sarcoma due to its variability between patients. The rarity of this disease must be adapted to the research of it, says Blay. Sarcoma has been shown to be a good model in which to develop treatments, adds Blay, demonstrated by the success of eribulin (Halaven) in liposarcoma.
Related Content: